Belite Bio to Participate in Four Upcoming Investor Conferences

Rhea-AI Summary

Belite Bio (NASDAQ: BLTE), a clinical-stage biopharmaceutical company specializing in degenerative retinal disease therapeutics, has announced its participation in four upcoming investor conferences in May 2025:

• Deutsche Bank Depositary Receipts Virtual Conference on May 15 at 12:30 PM ET
• H.C. Wainwright BioConnect Investor Conference at NASDAQ on May 20 at 5:00 PM ET
• Stifel Ophthalmology Forum on May 27 at 11:00 AM ET
• Benchmark's Healthcare House Call Conference on May 29 at 12:45 PM ET

Webcasts of all presentations will be available on Belite Bio's investor relations website and archived for 90 days.

SAN DIEGO, May 12, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in four upcoming investor conferences. Details of the presentations are as follows:

• Deutsche Bank Depositary Receipts Virtual Investor Conference (Virtual)
  • May 15, 2025, at 12:30 pm ET, corporate presentation
• H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ (New York, NY)
  • May 20, 2025, at 5:00 pm ET, fireside chat
• Stifel 2025 Ophthalmology Forum (Virtual)
  • May 27, 2025, at 11:00 am ET, fireside chat
• Benchmark's Healthcare House Call One-on-One Conference (Virtual)
  • May 29, 2025, at 12:45 pm ET, fireside chat

Webcast Link Instructions
A webcast of each presentation can be accessed under the "Events" tab on the investor relations section of the Belite Bio website at: https://investors.belitebio.com/presentations-events/events. The replays will be archived for 90 days following the presentation date.

About Belite Bio
Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, Facebook or visit us at www.belitebio.com.

Media and Investor Relations Contact:
Jennifer Wu
ir@belitebio.com

Julie Fallon
belite@argotpartners.com

FAQ

What investor conferences is BLTE participating in during May 2025?

Belite Bio is participating in four conferences: Deutsche Bank Depositary Receipts Virtual Conference (May 15), H.C. Wainwright BioConnect Investor Conference (May 20), Stifel Ophthalmology Forum (May 27), and Benchmark's Healthcare House Call Conference (May 29).

How can investors access Belite Bio's conference presentations?

Investors can access the webcasts through the 'Events' tab on Belite Bio's investor relations website at investors.belitebio.com. Replays will be available for 90 days after each presentation.

What is Belite Bio's main business focus?

Belite Bio is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for degenerative retinal diseases with significant unmet medical needs.

Which of BLTE's May 2025 conferences will be virtual vs in-person?

Three conferences will be virtual (Deutsche Bank, Stifel, and Benchmark), while the H.C. Wainwright BioConnect Conference will be held in-person at NASDAQ in New York.